美国 - 英文 - NLM (National Library of Medicine)

stat rx usa - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta™ (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. like other drugs with mu-opioid agonist activity, nucynta™ is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta™ is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta™ is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta™ is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregna

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

grunenthal ltd - tapentadol hydrochloride - oral tablet - 75mg

加拿大 - 英文 - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 75mg - tapentadol (tapentadol hydrochloride) 75mg - opiate agonists

美国 - 英文 - NLM (National Library of Medicine)

rebel distributors corp - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w